Nabriva Therapeutics (NASDAQ:NBRV) has been given a $7.00 price target by research analysts at HC Wainwright in a research note issued on Sunday, AnalystRatings.com reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 216.74% from the company’s current price.

The analysts wrote, “We employ a rNPV valuation model, driven by U.S. sales of: (1) lefamulin for CABP through 2028 (peak sales $460M); and (2) CONTEPO for cUTI through 2028 (peak sales $205M). We utilize a 15.0% discount rate for all cash flows, with zero terminal value after 2028, to arrive at our $7 price target (representing risk-adjusted per share values of about $6.50 for lefamulin and about $0.50 for CONTEPO). Risks to the attainment of our PT include failure to obtain FDA approval, unforeseen safety and/or tolerability issues, commercial sales trajectory meaningfully below then consensus expectations, and the dilution to current shareholders from additional equity offering(s).””

Several other research analysts have also recently weighed in on NBRV. ValuEngine upgraded shares of Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Gabelli upgraded shares of Nabriva Therapeutics from a “sell” rating to a “hold” rating and set a $2.00 price objective for the company in a research report on Thursday, May 2nd. Wedbush restated an “outperform” rating and issued a $5.00 price objective on shares of Nabriva Therapeutics in a research report on Friday, August 9th. BidaskClub cut shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 24th. Finally, Zacks Investment Research upgraded shares of Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Wednesday, August 14th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Nabriva Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $7.06.

NASDAQ:NBRV opened at $2.21 on Friday. Nabriva Therapeutics has a 1 year low of $1.12 and a 1 year high of $3.27. The firm has a 50 day moving average of $2.35 and a 200-day moving average of $2.39. The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $1.67 billion, a P/E ratio of -1.36 and a beta of 2.40.

Nabriva Therapeutics (NASDAQ:NBRV) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. Nabriva Therapeutics had a negative net margin of 3,602.24% and a negative return on equity of 139.52%. The company had revenue of $0.53 million during the quarter, compared to analysts’ expectations of $0.88 million. As a group, analysts forecast that Nabriva Therapeutics will post -1.1 EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the business. Morgan Stanley grew its position in Nabriva Therapeutics by 52.9% during the 2nd quarter. Morgan Stanley now owns 265,418 shares of the biotechnology company’s stock valued at $645,000 after purchasing an additional 91,869 shares during the last quarter. A.R.T. Advisors LLC purchased a new stake in Nabriva Therapeutics during the 2nd quarter valued at about $90,000. Parametric Portfolio Associates LLC grew its position in Nabriva Therapeutics by 180.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 52,272 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 33,656 shares during the last quarter. Renaissance Technologies LLC grew its position in Nabriva Therapeutics by 51.8% during the 2nd quarter. Renaissance Technologies LLC now owns 1,299,365 shares of the biotechnology company’s stock valued at $3,157,000 after purchasing an additional 443,600 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Nabriva Therapeutics by 92.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 323,857 shares of the biotechnology company’s stock valued at $719,000 after purchasing an additional 155,815 shares during the last quarter. Institutional investors own 3.10% of the company’s stock.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

See Also: Overbought

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.